RevBio, Inc.

About RevBio, Inc.

The standard of care for healing broken bones hasn't changed in over fifty years. Invasive metal hardware is still routinely used to fixate bones–often with less-than-optimal patient outcomes. RevBio® is a medical device company that has invented TETRANITE®, a regenerative bone adhesive currently in 150 patients across seven FDA approved clinical trials. Our patented “bone glue” is founded upon a comprehensive patent portfolio with global patent protection extending through 2042. Easily injectable into a range of musculoskeletal defects, TETRANITE has demonstrated superior performance over other standard of care options in curing speed and strength, rate of resorption, bone regeneration, and most critically wet-field adhesion. As a novel technology, TETRANITE is anticipated to receive a De Novo classification for several indications which will expedite the path to commercialization by Q3 2027. Bioengineered for a body of applications, the TETRANITE platform will address a total addressable market of over $10 billion in neurosurgical, orthopaedic and dental use cases.Inspired by the marine animal the sandcastle worm, Tetranite is simple chemistry. Bioengineered from the worm’s secreted protein, our synthetic adhesive is the only patented biomaterial which satisfies both the required and desired properties for a bone adhesive: wet field performance, multi-surface bonding, rapid mechanical stability, and controlled biodegradability. The properties of Tetranite™ include the ability to provide immediate fixation of bone to bone and bone to metal. This adhesive has been shown in multiple animal studies to be a non-toxic and effective way of repairing bone fractures and defects as well as securing implant devices. Existing data has also shown that Tetranite™ is reabsorbed and replaced with new bone during the natural process of bone remodeling by acting as a scaffold to facilitate bone growth over time.